{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:18Z","timestamp":1791919638432,"version":"4.3.4"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Pharmacokinetic\/pharmacodynamic (PK\/PD) integration models are used to investigate the antimicrobial activity characteristics of drugs targeting pathogenic bacteria through comprehensive analysis of the interactions between PK and PD parameters. PK\/PD models have been widely applied in the development of new drugs, optimization of the dosage regimen, and prevention and treatment of drug-resistant bacteria. In PK\/PD analysis, minimal inhibitory concentration (MIC) is the most commonly applied PD parameter. However, accurately determining MIC is challenging and this can influence the therapeutic effect. Therefore, it is necessary to optimize PD indices to generate more rational results. Researchers have attempted to optimize PD parameters using mutant prevention concentration (MPC)-based PK\/PD models, multiple PD parameter-based PK\/PD models, kill rate-based PK\/PD models, and others. In this review, we discuss progress on PD parameters for PK\/PD models to provide a valuable reference for drug development, determining the dosage regimen, and preventing drug-resistant mutations.<\/jats:p>","DOI":"10.3389\/fvets.2022.860472","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T04:04:23Z","timestamp":1648526663000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":49,"title":["Pharmacodynamic Parameters of Pharmacokinetic\/Pharmacodynamic (PK\/PD) Integration Models"],"prefix":"10.3389","volume":"9","author":[{"given":"Longfei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhe","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1126\/science.aaf9286","article-title":"Achieving global targets for antimicrobial resistance","volume":"353","author":"Laxminarayan","year":"2016","journal-title":"Science."},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"106368","DOI":"10.1016\/j.ijantimicag.2021.106368","article-title":"Antibiotic pharmacokinetic\/pharmacodynamic modeling: MIC, Pharmacodynamic indices, and beyond","volume":"2021","author":"Rao","year":"2021","journal-title":"Int J Antimicrob Agents."},{"key":"B4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-Informed drug development for anti-infectives: state of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin Pharmacol Therapeutics."},{"key":"B5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/pharmaceutics13060833","article-title":"The role of PK\/PD analysis in the development and evaluation of antimicrobials","volume":"13","author":"Rodr\u00edguez-Gasc\u00f3n","year":"2021","journal-title":"Pharmaceutics."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.4142\/jvs.2019.20.e40","article-title":"Pharmacokinetics\/Pharmacodynamics models of veterinary antimicrobial agents","volume":"20","author":"Luo","year":"2019","journal-title":"J Vet Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/jvp.12917","article-title":"The pharmacokinetic\/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: recent advances and critical appraisal","volume":"44","author":"Toutain","year":"2021","journal-title":"J Vet Pharmacol Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.coph.2008.06.010","article-title":"PK\/PD: new insights for antibacterial and antiviral applications","volume":"8","author":"Schmidt","year":"2008","journal-title":"Curr Opin Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"As\u00edn-Prieto","year":"2015","journal-title":"J Infect Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2165\/00003088-200544020-00005","article-title":"Pharmacokinetic\/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics","volume":"44","author":"Mouton","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/00003088-200544070-00007","article-title":"Relationship between minimum inhibitory concentration and stationary concentration revisited","volume":"44","author":"Mouton","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/cid\/cis473","article-title":"Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability","volume":"55","author":"Buyck","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1093\/jac\/dkz142","article-title":"Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision","volume":"73","author":"Mouton J","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1128\/AAC.48.2.369-377.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC","volume":"48","author":"Mueller","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tube.2009.08.002","article-title":"A simple in vitro PK\/PD model system to determine time\u2013kill curves of drugs against Mycobacteria","volume":"89","author":"Budha","year":"2009","journal-title":"Tuberculosis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jac\/dkg401","article-title":"Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing","volume":"52","author":"Zinner","year":"2003","journal-title":"J Antimicrob Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijantimicag.2004.09.012","article-title":"Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models","volume":"25","author":"Liu","year":"2005","journal-title":"Int J Antimicrob Agents."},{"key":"B19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejps.2018.11.006","article-title":"Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis","volume":"127","author":"Vaddady","year":"2019","journal-title":"Eur J Pharmaceut Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1128\/AAC.00662-11","article-title":"Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic\/pharmacodynamic model","volume":"56","author":"Meletiadis","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jac\/15.suppl_a.125","article-title":"In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives","volume":"15","author":"Blaser","year":"1985","journal-title":"J Antimicrob Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1128\/AAC.37.9.1756","article-title":"Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection","volume":"37","author":"Marchbanks","year":"1993","journal-title":"Antimicrob Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.4172\/2167-1052.S1-007","article-title":"The hollow fiber infection model for antimicrobial pharmacodynamics and pharmacokinetics","volume":"1","author":"Cadwell","year":"2012","journal-title":"Adv Pharmacoepidem Drug Safety S."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1128\/AAC.49.8.3178-3181.2005","article-title":"Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance","volume":"49","author":"Gumbo","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"B25","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1128\/AAC.00065-10","article-title":"The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression","volume":"54","author":"Louie","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1128\/AAC.01439-07","article-title":"Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis","volume":"52","author":"Louie","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3389\/fphar.2021.682135","article-title":"Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for Zoliflodacin against neisseria gonorrhoeae in a dynamic hollow fiber infection model","volume":"12","author":"Jacobsson","year":"2021","journal-title":"Front Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijid.2019.08.026","article-title":"A translational pharmacokinetic\/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam","volume":"89","author":"Bhagunde","year":"2019","journal-title":"Int J Infect Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1093\/jac\/dkab160","article-title":"Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting","volume":"76","author":"Sadouki","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/jvp.12385","article-title":"Pharmacokinetic\/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida","volume":"40","author":"Dorey","year":"2017","journal-title":"J Vet Pharmacol Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0177568","DOI":"10.1371\/journal.pone.0177568","article-title":"Pharmacokinetic\/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida","volume":"12","author":"Dorey","year":"2017","journal-title":"PLoS ONE"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12917-017-1128-y","article-title":"Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic\/pharmacodynamic modelling","volume":"13","author":"Dorey","year":"2017","journal-title":"BMC Vet Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1090-0233(02)00258-7","article-title":"Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids","volume":"165","author":"Aliabadi","year":"2003","journal-title":"Vet J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1128\/AAC.47.2.626-635.2003","article-title":"Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids","volume":"47","author":"Aliabadi","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2460\/ajvr.2001.62.1979","article-title":"Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration","volume":"62","author":"Aliabadi","year":"2001","journal-title":"Am J Vet Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/jvp.12093","article-title":"Pharmacokinetic\u2013pharmacodynamic integration and modelling of florfenicol in calves","volume":"37","author":"Sidhu","year":"2014","journal-title":"J Vet Pharmacol Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.rvsc.2020.10.003","article-title":"Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid","volume":"135","author":"Li","year":"2021","journal-title":"Res Vet Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tvjl.2013.12.015","article-title":"Pharmacokinetics and ex vivo pharmacodynamics of cefquinome in porcine serum and tissue cage fluids","volume":"199","author":"Zhang","year":"2014","journal-title":"Vet J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fphar.2017.00392","article-title":"Pharmacokinetic\/pharmacodynamic modeling of tulathromycin against Pasteurella multocida in a porcine tissue cage model","volume":"8","author":"Zhou","year":"2017","journal-title":"Front Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"104097","DOI":"10.1016\/j.micpath.2020.104097","article-title":"Integration of PK\/PD for dose optimization of aditoprim against Trueperella pyogenes causing endometritis in bovines","volume":"142","author":"Maan","year":"2020","journal-title":"Microb Pathog."},{"key":"B41","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fphar.2017.00542","article-title":"Pharmacokinetic and pharmacodynamic evaluation of marbofloxacin and PK\/PD modeling against Escherichia coli in pigs","volume":"8","author":"Lei","year":"2017","journal-title":"Front Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.vetmic.2018.02.027","article-title":"Pharmacokinetic\/pharmacodynamic assessment of cefquinome against Actinobacillus pleuropneumoniae in a piglet tissue cage infection model","volume":"219","author":"Zhang","year":"2018","journal-title":"Vet Microbiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3389\/fmicb.2015.00759","article-title":"In vivo antimicrobial activity of marbofloxacin against Pasteurella multocida in a tissue cage model in calves","volume":"6","author":"Cao","year":"2015","journal-title":"Front Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12917-017-1099-z","article-title":"Integrated pharmacokinetic\u2013pharmacodynamic (PK\/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets","volume":"13","author":"Zeng","year":"2017","journal-title":"BMC Vet Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/jvp.12705","article-title":"Pharmacokinetic\/pharmacodynamic integration of cefquinome against Pasteurella Multocida in a piglet tissue cage model","volume":"42","author":"Zhang","year":"2019","journal-title":"J Vet Pharmacol Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.3389\/fmicb.2018.02445","article-title":"Pharmacokinetic\/pharmacodynamic integration to evaluate the changes in susceptibility of Actinobacillus pleuropneumoniae after repeated administration of Danofloxacin","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3389\/fmicb.2019.01638","article-title":"Amoxicillin administration regimen and resistance mechanisms of Staphylococcus aureus established in tissue cage infection model","volume":"10","author":"Yao","year":"2019","journal-title":"Front Microbiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3389\/fmicb.2016.00874","article-title":"Relationship between cefquinome PK\/PD parameters and emergence of resistance of Staphylococcus aureus in rabbit tissue-cage infection model","volume":"7","author":"Xiong","year":"2016","journal-title":"Front Microbiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12917-014-0297-1","article-title":"In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model","volume":"10","author":"Zhang","year":"2014","journal-title":"BMC Vet Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/jac\/dkg339","article-title":"Pharmacokinetic\/pharmacodynamic relationship of danofloxacin against Mannheimia haemolytica in a tissue-cage model in calves","volume":"52","author":"Greko","year":"2003","journal-title":"J Antimicrob Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.3389\/fmicb.2020.616685","article-title":"In vivo pharmacokinetic and pharmacodynamic (PK\/PD) modeling and establishment of the PK\/PD Cutoff of florfenicol against pasteurella multocida in ducks","volume":"11","author":"Xiao","year":"2021","journal-title":"Front Microbiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12917-018-1698-3","article-title":"In vivo pharmacokinetic\/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens","volume":"14","author":"Xiao","year":"2018","journal-title":"BMC Vet Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fphar.2018.00391","article-title":"In Vivo Pharmacokinetic\/Pharmacodynamic profiles of danofloxacin in rabbits infected with Salmonella typhimurium after oral administration","volume":"9","author":"Xiao","year":"2018","journal-title":"Front Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3389\/fmicb.2018.01038","article-title":"Pharmacokinetics and pharmacodynamics of tildipirosin against Pasteurella multocida in a murine lung infection model","volume":"9","author":"Zeng","year":"2018","journal-title":"Front Microbiol."},{"key":"B55","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3389\/fmicb.2017.00926","article-title":"The PK\u2013PD relationship and resistance development of danofloxacin against Mycoplasma gallisepticum in an In Vivo infection model","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Microbiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fphar.2019.01090","article-title":"Pharmacokinetics and pharmacodynamics of gamithromycin treatment of Pasteurella multocida in a murine lung infection model","volume":"10","author":"Yang","year":"2019","journal-title":"Front Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e02031","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11095-020-02977-8","article-title":"Pharmacokinetics\/Pharmacodynamics evaluation of flomoxef against extended-spectrum beta-lactamase-producing Escherichia coli in vitro and in vivo in a murine thigh infection model","volume":"38","author":"Tashiro","year":"2021","journal-title":"Pharm Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3389\/fmicb.2020.511356","article-title":"Increased antimicrobial activity of colistin in combination with gamithromycin against pasteurella multocida in a neutropenic murine lung infection model","volume":"11","author":"Li","year":"2020","journal-title":"Front Microbiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3389\/fphar.2021.658558","article-title":"Pharmacokinetics and pharmacodynamics of nemonoxacin in a neutropenic murine lung infection model against streptococcus pneumoniae","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jgar.2020.11.014","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model","volume":"24","author":"Watanabe","year":"2021","journal-title":"J Glob Antimicrob Resistance."},{"key":"B62","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1128\/aac.32.3.289","article-title":"Role of pharmacokinetics in the outcome of infections","volume":"32","author":"Drusano","year":"1988","journal-title":"Antimicrob Agents Chemother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0924-8579(02)00031-6","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs","volume":"19","author":"Mouton","year":"2002","journal-title":"Int J Antimicrob Agents."},{"key":"B65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2885.2004.00618.x","article-title":"PK\u2013PD integration and PK\u2013PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology","volume":"27","author":"Lees","year":"2004","journal-title":"J Vet Pharmacol Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00004850-199710006-00006","article-title":"Basic concepts of pharmacokinetic\/pharmacodynamic (PK\/PD) modelling","volume":"35","author":"Meibohm","year":"1997","journal-title":"Int J Clin Pharmacol Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for Gram-negative bacteria? A systematic review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-03970-9","article-title":"Pharmacokinetic and pharmacodynamic modeling of cyadox against Clostridium perfringens in swine","volume":"7","author":"Yan","year":"2017","journal-title":"Sci Rep."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.clinthera.2016.06.015","article-title":"Pharmacokinetic and pharmacodynamic principles of anti-infective dosing","volume":"38","author":"Onufrak","year":"2016","journal-title":"Clin Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jac\/dki241","article-title":"Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models","volume":"56","author":"Girard","year":"2005","journal-title":"J Antimicrob Chemother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"B73","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2133\/dmpk.DMPK-14-RG-013","article-title":"A proposal of a pharmacokinetic\/pharmacodynamic (PK\/PD) index map for selecting an optimal PK\/PD index from conventional indices (AUC\/MIC, Cmax\/MIC, and TAM) for antibiotics","volume":"29","author":"Kitamura","year":"2014","journal-title":"Drug Metab Pharmacokinet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-3164.2009.00856.x","article-title":"New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach","volume":"20","author":"Blondeau","year":"2009","journal-title":"Vet Dermatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2004.11782371","article-title":"The role of PK\/PD parameters to avoid selection and increase of resistance: mutant prevention concentration","volume":"16","author":"Blondeau","year":"2004","journal-title":"Journal of Chemotherapy."},{"key":"B76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/jac\/dkg269","article-title":"The mutant selection window and antimicrobial resistance","volume":"52","author":"Drlica","year":"2003","journal-title":"J Antimicrob Chemother."},{"key":"B77","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated","volume":"44","author":"Drlica","year":"2007","journal-title":"Clin Infect Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1086\/338571","article-title":"Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window","volume":"185","author":"Xilin","year":"2002","journal-title":"J Infect Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1086\/508752","article-title":"The mutant selection window in rabbits infected with Staphylococcus aureus","volume":"194","author":"Cui","year":"2006","journal-title":"J Infect Dis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/eva.12903","article-title":"Evolution of antibiotic cross-resistance and collateral sensitivity in Staphylococcus epidermidis using the mutant prevention concentration and the mutant selection window","volume":"13","author":"Lozano-Huntelman","year":"2020","journal-title":"Evol Appl."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1128\/AAC.00975-10","article-title":"Mutant prevention concentration-based pharmacokinetic\/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus","volume":"55","author":"Liang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"B82","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41429-017-0016-9","article-title":"Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid","volume":"71","author":"Alieva","year":"2018","journal-title":"J Antibiot."},{"key":"B83","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/978-3-319-78538-7_21","article-title":"PK\/PD-based prediction of \u201canti-mutant\u201d antibiotic exposures using in vitro dynamic models","volume-title":"Antimicrobial Resistance in the 21st Century","author":"Firsov","year":"2018"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00134-017-4780-6","article-title":"The role of infection models and PK\/PD modelling for optimising care of critically ill patients with severe infections","volume":"43","author":"T\u00e4ngd\u00e9n","year":"2017","journal-title":"Intensive Care Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fmicb.2016.00466","article-title":"Correlation of PK\/PD indices with resistance selection for cefquinome against Staphylococcus aureus in an in vitro model","volume":"7","author":"Li","year":"2016","journal-title":"Front Microbiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/mdr.2021.0228","article-title":"Comparative minimal inhibitory and mutant prevention concentration of eight antimicrobial agents against Klebsiella pneumoniae","volume":"28","author":"Yang","year":"2021","journal-title":"Microbial Drug Resistance"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e0210154","DOI":"10.1371\/journal.pone.0210154","article-title":"Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis","volume":"14","author":"Blondeau","year":"2019","journal-title":"PLoS ONE"},{"key":"B88","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1023\/A:1016085402278","article-title":"Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro","volume":"13","author":"Nolting","year":"1996","journal-title":"Pharm Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1128\/AAC.48.10.3670-3676.2004","article-title":"Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens","volume":"48","author":"Regoes","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-016-0838-9","article-title":"Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae","volume":"16","author":"Foerster","year":"2016","journal-title":"BMC Microbiol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e00788","DOI":"10.1128\/AAC.00788-20","article-title":"Sequential time-kill: a simple experimental trick to discriminate between PK\/PD models with distinct heterogeneous sub-populations versus homogenous population with adaptive resistance","volume":"64","author":"Chauzy","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/pr.111.005769","article-title":"Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs","volume":"65","author":"Nielsen","year":"2013","journal-title":"Pharmacol Rev."},{"key":"B93","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/pharmaceutics14020246","article-title":"Application of semi-mechanistic pharmacokinetic and pharmacodynamic model in antimicrobial resistance","volume":"14","author":"Mi","year":"2022","journal-title":"Pharmaceutics."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1128\/AAC.01478-08","article-title":"Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa","volume":"54","author":"Gr\u00e9goire","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/jac\/dkx537","article-title":"A mathematical model-based analysis of the time-kill kinetics of ceftazidime\/avibactam against Pseudomonas aeruginosa","volume":"73","author":"Sy","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/antibiotics10121485","article-title":"Predicting antimicrobial activity at the target site: pharmacokinetic\/pharmacodynamic indices versus time\u2013kill approaches","volume":"10","author":"van Os","year":"2021","journal-title":"Antibiotics."},{"key":"B97","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/jac\/dkz440","article-title":"A novel mechanism-based pharmacokinetic\u2013pharmacodynamic (PKPD) model describing ceftazidime\/avibactam efficacy against \u03b2-lactamase-producing Gram-negative bacteria","volume":"75","author":"Kristoffersson","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e02070","DOI":"10.1128\/AAC.02070-19","article-title":"Extension of pharmacokinetic\/pharmacodynamic (PK\/PD) time-kill studies to include LPS\/endotoxin release from E. coli exposed to cefuroxime","volume":"64","author":"Thorsted","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B99","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/jac\/dku431","article-title":"Time\u2013kill kinetics of antibiotics active against rapidly growing mycobacteria","volume":"70","author":"Ferro B","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"B100","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fmicb.2016.00653","article-title":"The PK\/PD interactions of doxycycline against Mycoplasma gallisepticum","volume":"7","author":"Zhang","year":"2016","journal-title":"Front Microbiol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"751957","DOI":"10.3389\/fvets.2021.751957","article-title":"Kill rate and evaluation of ex vivo PK\/PD integration of cefquinome against Actinobacillus pleuropneumoniae","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Vet Sci"},{"key":"B102","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1365-2672.2010.04876.x","article-title":"Kill rate of mastitis pathogens by a combination of cefalexin and kanamycin","volume":"110","author":"Maneke","year":"2011","journal-title":"J Appl Microbiol."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.860472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T16:15:30Z","timestamp":1675095330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.860472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":102,"alternative-id":["10.3389\/fvets.2022.860472"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2022.860472","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"article-number":"860472"}}